Daily Sepsis Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Three mechanistic studies advance sepsis biology and therapeutic strategies. A covalent allosteric IRF3 inhibitor (Sim-9) suppresses type I interferon signaling and mitigates inflammation in murine sepsis, while epigenetic control of mitochondrial danger signaling (DNMT1–TFAM–mtDNA–cGAS-STING) and PDYN-mediated inhibition of microglial pyroptosis delineate actionable targets for sepsis-induced organ dysfunction.
Research Themes
- Allosteric inhibition of IRF3 as a sepsis immunomodulatory strategy
- Epigenetic regulation of mitochondrial danger signaling in sepsis-induced organ dysfunction
- Targeting microglial pyroptosis in sepsis-associated encephalopathy
Selected Articles
1. A sinomenine derivative protects life-threatening inflammatory injuries via covalently binding to a novel allosteric inhibition site of IRF3.
Using phenotypic high-throughput screening, the authors identified a sinomenine derivative (Sim-9) that covalently binds IRF3 at Cys222, allosterically disrupting pLxIS-mediated interactions and type I IFN activation. Sim-9 suppressed IFN responses across multiple human and murine cell systems and mitigated inflammatory injury in CLP-induced sepsis and pancreatitis models.
Impact: This work introduces a first-in-class covalent allosteric IRF3 inhibitor and reveals a previously unrecognized druggable surface on IRF3, opening a new avenue for immunomodulation in sepsis.
Clinical Implications: If safety and pharmacology are confirmed, IRF3 allosteric inhibition could become a targeted adjunct to dampen hyperinflammatory responses in sepsis, informing biomarker-driven patient selection.
Key Findings
- Phenotypic screening identified sinomenine as a type I IFN inhibitor; among 24 derivatives, Sim-9 potently inhibited TLR/RLR/STING-triggered IFN responses at 2.5–10 μM.
- Sim-9 covalently binds IRF3 at Cys222, alters the pLxIS motif-binding surface, blocks interactions with TRIF/MAVS/STING, and prevents IRF3 homodimerization.
- In vivo, Sim-9 (30, 60 mg/kg, i.p.) protected against CLP-induced sepsis inflammation and improved cerulein-induced pancreatitis.
Methodological Strengths
- Phenotype-based high-throughput, activity-guided screening linked to mechanistic validation
- Cross-validation across multiple human/murine cell lines and two in vivo disease models
Limitations
- Pharmacokinetics, toxicity, and off-target profiling are not reported
- Translational efficacy, dosing window, and safety in humans remain unknown
Future Directions: Elucidate IRF3–Sim-9 structural complex, optimize SAR, characterize PK/PD and safety, and test therapeutic dosing in infectious sepsis models with biomarker stratification.
The severe inflammation associated with infectious or inflammatory diseases significantly contributes to mortality. Interferon regulatory factor 3 (IRF3) represents a potential anti-inflammatory target, but the development of IRF3 inhibitors has not yielded satisfactory results to date. In this study, we established a phenotype-based high-throughput screening system to conduct activity-guided hierarchical screening of clinical frequently used anti-inflammatory and anti-rheumatic herbal extracts and compounds. Employing a Gaussia-luciferase reporter system driven by the IFNB1 promoter, we identified sinomenine as a potent type I interferon (IFN) inhibitor from a set of 28 anti-inflammatory herbal products. Furthermore, among 24 synthesized sinomenine derivatives modified by various electrophilic groups, Sim-9 (2.5-10 μM) dose-dependently inhibited IFN responses triggered by TLRs, RLRs, and STING activation in mouse RAW264.7 cells and in human THP-1 cells, HT-29 cells and A549 cells. We demonstrated that Sim-9, by covalently binding to Cys222, induced a conformational change in the pLxIS motif-binding surface of IRF3, thus blocking its interaction with upstream adapters, including TRIF, MAVS and STING, and subsequent homodimerization of IRF3 itself, which were all essential for activation of type I IFN responses. In in vivo experiments, we showed that injection of Sim-9 (30, 60 mg/kg, i.p.) effectively protected against devastating inflammation in cecal ligation and puncture (CLP)-induced sepsis in mice, and improved cerulein-induced pancreatitis by inhibiting IRF3. Our study discovers Sim-9 as a novel covalent allosteric inhibitor of IRF3 and reveals that the pLxIS motif binding surface represents a previously uncharacterized druggable target for IRF3 activation, providing a promising therapeutic strategy for the treatment of severe inflammatory injuries.
2. DNMT1 knockdown mitigates sepsis-induced myocardial dysfunction by preventing TFAM-mediated mitochondrial DNA cytosolic escape and subsequent cGAS-STING to regulate macrophage M2 polarization.
In an LPS-induced SIMD model, DNMT1 inhibition via decitabine pretreatment improved survival and cardiac function and reduced cardiomyocyte apoptosis. Mechanistically, DNMT1 depletion upregulated TFAM, preserved mitochondrial integrity, limited mtDNA cytosolic escape, inactivated cGAS-STING signaling, and promoted macrophage M2 polarization; perturbation of TFAM or cGAS reversed these benefits.
Impact: Defines an epigenetic–mitochondrial danger signaling axis driving SIMD and shows targetability with an approved DNMT1 inhibitor in vivo, suggesting a translational path.
Clinical Implications: Findings support exploring DNMT1–TFAM modulation to prevent or mitigate SIMD, guiding the design of timing-sensitive trials and biomarker strategies around mtDNA/cGAS-STING activity.
Key Findings
- Decitabine pretreatment improved survival and cardiac function and reduced cardiomyocyte apoptosis in LPS-induced SIMD mice.
- DNMT1 knockdown increased TFAM, alleviated mitochondrial dysfunction, limited cytosolic mtDNA release, and inactivated cGAS-STING signaling.
- TFAM downregulation or cGAS upregulation reversed the protective effects, confirming pathway causality; in vivo validation supported the mechanism.
Methodological Strengths
- Integrated in vivo and in vitro mechanistic validation with genetic perturbations (DNMT1 knockdown, TFAM modulation, cGAS upregulation)
- Use of functional cardiac outcomes alongside molecular pathway readouts
Limitations
- Model relies on LPS and decitabine pretreatment two weeks prior, limiting clinical translatability for acute sepsis
- Potential off-target and global epigenetic effects of DNMT1 inhibition are not fully characterized
Future Directions: Assess therapeutic (post-insult) dosing windows, cardiac-specific targeting of DNMT1/TFAM, and biomarker-driven patient selection based on mtDNA and cGAS-STING activation.
Sepsis-induced myocardial dysfunction (SIMD) is a prevalent complication of sepsis and correlates with high mortality. The study investigated the effect of inhibiting DNA methyltransferase 1 (DNMT1) on SIMD and its potential mechanism. In this study, an SIMD mouse model was established using lipopolysaccharide (LPS). Two weeks before modeling, mice were intraperitoneally injected with the DNMT1 inhibitor decitabine or Vehicle. Pretreatment with the DNMT1 inhibitor decitabine in SIMD mice improved survival, cardiac function, and reduced cardiomyocyte apoptosis. In LPS-stimulated RAW264.7 macrophages, DNMT1 knockdown promoted M2 polarization while suppressing M1 polarization, and reduced apoptosis in cardiomyocytes cultured with conditioned media. Mechanistically, DNMT1 depletion upregulated mitochondrial transcription factor A (TFAM) by reducing DNA methylation modification, which alleviated mitochondrial dysfunction and limited mitochondrial DNA (mtDNA) release into the cytosol. This subsequently inactivated the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. TFAM downregulation reversed the improvement in mitochondrial function achieved by DNMT1 knockdown, while cGAS upregulation averted DNMT1 knockdown-inhibited mtDNA cytosolic escape-mediated cGAS-STING. In vivo validation confirmed this mechanism. Collectively, DNMT1 regulates mitochondrial dysfunction and cytosolic mtDNA release by modulating TFAM promoter DNA methylation, thereby activating the cGAS-STING pathway, further influencing macrophage polarization and cardiomyocyte apoptosis, and ultimately exacerbating SIMD.
3. Suppression of the PI3K/AKT/mTOR Signaling Pathway by PDYN Alleviates Sepsis-Associated Encephalopathy in Mice.
In CLP-induced SAE, PDYN reduced neuronal injury and cognitive deficits, suppressing microglial pyroptosis and inflammatory cytokines. Mechanistically, PDYN acts via inhibition of the PI3K/AKT/mTOR pathway, as the PI3K activator 740Y-P reversed its anti-pyroptotic effects.
Impact: Identifies PDYN and the PI3K/AKT/mTOR–pyroptosis axis as tractable targets in sepsis-associated encephalopathy, integrating behavioral, histologic, and signaling evidence.
Clinical Implications: Supports development of adjunctive neuroprotective strategies targeting microglial pyroptosis in SAE, potentially guiding pharmacologic modulation of PI3K/AKT/mTOR signaling.
Key Findings
- PDYN reduced neuronal damage and cognitive impairment in CLP-induced sepsis-associated encephalopathy.
- PDYN inhibited microglial pyroptosis and inflammatory cytokine secretion in vivo and in vitro.
- The anti-pyroptotic effect of PDYN is mediated by PI3K/AKT/mTOR inhibition; PI3K activator 740Y-P promoted pyroptosis and counteracted PDYN’s effects.
Methodological Strengths
- Use of CLP model with comprehensive behavioral testing (Morris water maze, novel object recognition, open field)
- Multimodal assessments including histology (TUNEL, Nissl, H&E) and pathway analysis (Western blot)
Limitations
- Preclinical findings without pharmacologic PDYN modulation or clinical validation
- Mechanistic focus on PI3K/AKT/mTOR may not capture other pathways contributing to SAE
Future Directions: Develop pharmacologic modulators of PDYN signaling, test therapeutic timing post-sepsis onset, and validate in diverse SAE models and species.
BACKGROUND: Microglial pyroptosis-mediated neuroinflammation is a key pathogenic mechanism in Sepsis-Associated Encephalopathy (SAE). However, the role of prodynorphin (PDYN) in SAE and the relationship between PDYN and microglial pyroptosis remain unknown. METHODS: Mice were subjected to cecal ligation and puncture (CLP) or sham surgery. Microglial cells were treated with lipopolysaccharide (LPS) in vitro. Cognitive function was assessed using the Morris water maze, novel object recognition, and open field tests. Transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) staining was used to observe glial apoptosis; Nissl staining was used to observe microglial infiltration; H&E staining was used to detect histopathological changes. Pyroptosis and the expression levels of relevant signaling molecules were assessed by Western blot analysis. RESULTS: PDYN protected against neuronal damage and cognitive impairment in septic mice. PDYN inhibits microglial pyroptosis and secretion of inflammatory cytokines in vivo and in vitro. Further examination revealed that PDYN inhibits microglial pyroptosis by inhibiting the PI3K/AKT/mTORC pathway. Moreover, the PI3K activator 740Y-P promoted microglial pyroptosis by activating the PI3K/AKT/mTORC pathway. CONCLUSION: This study reveals, for the first time, that PDYN exerts neuroprotective effects in SAE by suppressing microglial pyroptosis through inhibition of the PI3K/AKT/mTOR signaling pathway. These findings identify PDYN and the PI3K/AKT/mTOR-pyroptosis axis as novel therapeutic targets for SAE, providing a mechanistic foundation for developing adjunctive neuroprotective strategies alongside standard sepsis care.